ALEC stock forecast, quote, news & analysis
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases... Show more
Why Alector (ALEC) Stock Is Up +70% in the Last 30 Days
Key Takeaways
- Alector (ALEC) shares climbed roughly 70% over the past 30 days, rising from about $1.43 to $2.43, driven by a better-than-expected quarterly report and renewed momentum in its neurodegeneration pipeline.
- The stock's second-quarter results exceeded consensus estimates, with a narrower loss per share and revenue that surpassed analyst forecasts.
- Over the last quarter, ALEC gained approximately 10%, reflecting a recovery from a multi-month decline rather than a sustained uptrend.
- The company remains deeply unprofitable, with modest collaboration revenue and a cash burn that keeps balance-sheet risk in focus.
- Consensus analyst sentiment is a "Hold," with price targets spanning a wide range that reflects binary clinical and funding risk.
Alector (ALEC) Company Overview and Market Position
Alector, Inc. is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company develops immuno-neurology therapies designed to slow or counteract the progression of neurodegenerative diseases by engaging the brain's innate immune system. Its core focus is on conditions such as Alzheimer's disease, frontotemporal dementia (FTD), and Parkinson's disease.
Alector's pipeline includes latozinemab and nivisnebart, progranulin-elevating antibodies being developed in collaboration with GSK, as well as the AL050 enzyme replacement program and a proprietary "Alector Brain Carrier" platform intended to help transport therapeutics across the blood-brain barrier. Investors follow the stock closely because its value is tied to upcoming clinical readouts, which carry significant binary risk alongside potentially large upside.
Alector (ALEC) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ALEC advanced approximately 70%, climbing from a closing price near $1.43 to about $2.43. The move accelerated sharply in mid-August, with elevated trading volume and consecutive sessions of double-digit percentage gains that pushed the shares well above their 50-day simple moving average of roughly $1.69.
The quarterly picture is more measured. Over the trailing three months, the stock gained close to 10%, having traded near $2.21 earlier in the period before a summer slide took it toward the low-$1.40s. In that context, the recent 30-day surge largely represents a sharp recovery off a depressed base, with the shares still trading well below their 52-week high of $3.40 and above their 52-week low of $1.09.
What Drove ALEC Stock Price in the Last 30 Days
The primary catalyst was Alector's second-quarter earnings report. The company reported a loss of $0.21 per share, beating the consensus estimate of a $0.23 loss, while revenue of $3.32 million exceeded analyst forecasts that had clustered near $1.4 million to $1.7 million. The stock rose roughly 23% in a single session on heavy volume following the results.
Beyond the headline beat, investors appeared to respond to a narrowing loss trajectory and management's continued emphasis on near-term clinical catalysts, including data readouts for its latozinemab program and progress on the Alector Brain Carrier platform. The move also reflected short-covering and momentum-driven buying in a low-float, low-priced name, with trading volumes running several times above their historical average during the rally.
What Drove ALEC Stock Performance Over the Last Quarter
The broader quarterly trend was shaped by a pullback followed by a sharp rebound. Earlier in the period, the shares drifted lower as persistent cash burn, declining year-over-year revenue, and analyst caution weighed on sentiment. Research coverage highlighted the combination of a fragile balance sheet, negative shareholders' equity, and ongoing net losses, which kept the stock under pressure near multi-year lows.
The subsequent recovery was driven by the earnings beat and a reset of investor expectations around the company's pipeline. Institutional ownership remains high at more than 85% of shares outstanding, while insider sales during the quarter — including transactions by the CEO and CFO — provided a counterweight to the improving near-term narrative. The net result was a modest quarterly gain that conceals considerable intra-period volatility.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a broader universe of hundreds of bots that trade thousands of tickers. Only the top-performing and most relevant bots are surfaced in this section, helping users quickly identify strategies that are currently generating standout results. Each bot varies in its underlying strategy, trading timeframe, and performance metrics, so the section offers a useful starting point for comparing approaches rather than a one-size-fits-all recommendation. Traders interested in systematic, data-driven signals may find the page a practical way to explore automated strategies across a wide range of securities.
ALEC Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important factors for ALEC are clinical and financial. Upcoming data readouts for latozinemab and progress on the Alector Brain Carrier platform are the central catalysts that could reshape the company's valuation in either direction. Investors should also monitor quarterly cash balances, which stood near $173 million in the most recent period, against an annual net loss that has exceeded $117 million on a trailing basis, as funding decisions and potential dilution remain key risks.
Analyst expectations are mixed, with a consensus "Hold" rating and price targets ranging widely from about $1.00 to $6.00, underscoring the binary nature of the investment. The next quarterly report, expected in early November, will provide an updated view on collaboration revenue, expense discipline, and the company's cash runway. As with all clinical-stage biotechs, trial outcomes and regulatory developments will remain the dominant drivers of share-price direction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALEC's RSI Indicator recovers from overbought zone
The 10-day RSI Indicator for ALEC moved out of overbought territory on August 20, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 instances where the indicator moved out of the overbought zone. In of the 17 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ALEC broke above its upper Bollinger Band on August 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on ALEC as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ALEC just turned positive on July 28, 2026. Looking at past instances where ALEC's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
ALEC moved above its 50-day moving average on August 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ALEC crossed bullishly above the 50-day moving average on August 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 184 cases where ALEC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.569) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (18.484) is also within normal values, averaging (444.692).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics for Alzheimer's disease and other neurodegenerative disorders
Industry Biotechnology